This site is intended for US healthcare professionals only

AccessPlus

See LESS Obstacles to Treatment and
See MORE Access for Patients

AccessPlus Program offers streamlined patient reimbursement support services that are easily integrated into your patient processing system. AccessPlus supports your patients with comprehensive services built around your practice needs:

Get an Overview of the YUTIQ AccessPlus Program.

The YUTIQ AccessPlus Program Journey

Product decision

Upon selecting YUTIQ, complete and submit patient enrollment form to AccessPlus by faxing it to 1-866-783-3124.

Insurance coordination

Upon receipt of the enrollment form, AccessPlus will begin the benefits investigation process. Support services include:

  1. Estimated patient out-of-pocket costs
  2. Prior authorizations
  3. Management of disputes, denials, and appeals
  4. Patient co-pay assistance

Fulfillment

Once AccessPlus notifies practice of insurance approval, practice contacts specialty distributor.

  1. YUTIQ will be delivered directly to your office from a distributor via specialty pharmacy or buy-and-bill.

Patient Confirmation

Practice confirms injection appointment with patient when YUTIQ is available.

Buy-and-Bill Reimbursement Process when Accessing YUTIQ

Claim Processing

File claim with patient’s insurance provider.

Adjudication

Payor adjudicates claim; turnaround time will vary depending on the payor.

Payor reimbursement

Healthcare provider is reimbursed by payor (commercial insurance, Medicare, and/or Medicaid).

Co-pay reimbursement

HCP submits Explanation of Benefits, Claim Form, and Co-pay Request Form to AccessPlus to initiate the process for potential co-pay reimbursement.

Consignment replacement

See options here

Benefits Investigation

Let us help you determine your patients’ coverage for YUTIQ

  • Complete the Patient Enrollment Form to initiate the benefits investigation
  • A Summary of Patient Benefits will be provided, typically within 48 hours
  • Prior authorization requirements with payor-specific processes and forms will be provided
  • Patient out-of-pocket responsibility and financial assistance options for YUTIQ are available

Reimbursement Support

  • Coding and billing guidance
  • Prior authorization assistance
  • Claims follow-up
  • Appeals support
  • Specialty pharmacy prescription referral routing and follow-up

Financial Assistance

Let us help you determine your patients’ coverage for YUTIQ

YUTIQ CoPay Program

The YUTIQ CoPay Program provides assistance toward product-specific copay, co-insurance and insurance deductibles for YUTIQ that exceed $25.* Qualifying patients are responsible for a maximum of $25.00 out-of-pocket costs.

To help your patients with their out-of-pocket costs for YUTIQ, the YUTIQ CoPay Program is available for eligible patients who have commercial or private insurance.  There is no income eligibility requirement. Eligibility requirements include:

  • Patient must have commercial or private insurance that covers YUTIQ for the FDA-labeled indication.
  • Patient out-of-pocket cost for YUTIQ must exceed $25.
  • Patient must be a resident of the United States or a US territory.
  • Max benefit of $4,500 per eye, per year.

*The program does not cover or provide support for procedures, supplies, or physician-related services associated with YUTIQ. Only product-specific copay, co-insurance and insurance deductibles are covered. This program is not valid where prohibited by law, taxed or restricted. Alimera Sciences reserves the right to change or cancel this offer or eligibility terms at any time without notice.

YUTIQ Patient Assistance Program

The YUTIQ Patient Assistance Program provides YUTIQ free of charge to eligible patients who are uninsured or lack coverage for YUTIQ. Eligibility requirements include:

  • Uninsured or lack coverage for YUTIQ
  • YUTIQ must be prescribed per the FDA-labeled indication
  • Patient must be a resident of the United States
  • Patient must have a financial need
  • Based on total adjusted annual household income of $100,000 or less

The process:

  1. Fax the completed and signed PAP application to AccessPlus at 1-866-783-3124.
  2. The application will be reviewed, and an approval decision will be made within 5 business days.
  3. The provider office and the patient will receive a letter with the approval status of the application.
  4. AccessPlus will coordinate shipment of YUTIQ to your office upon approval of the patient application.

Download the YUTIQ Patient Assistance Program (PAP)

Product Acquisition

YUTIQ is Available Through Specialty Distributors

Specialty distributorPhone NumberFax NumberItem Order Number
Besse1-513-851-23451-513-851-329910243067
McKesson Specialty Health1-855-477-98001-800-800-56735016150
McKesson Plasma & Biologics1-877-625-25661-888-752-76262842318
Code typeCodeDescriptor
HCPCSJ7314Injection, fluocinolone acetonide, intravitreal implant (YUTIQ), 0.01 mg (bill for 18 units)
10-digit NDC
11-digit NDC
68611-180-01
68611-0180-01
YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg
Link to Healthcare Professionals Site
The information contained on this site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023.

References

  1. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-006
  2. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-001
  3. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-003
  4. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023.
  5. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-002.

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023
  2. Thorne JE, Suhler E, Skup M, et al. Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis. JAMA Ophthalmol. 2016;134(11):1237-1245. 2016;134:1237-1245.
  3. Chorich LJ III, et a;. Diagnosis and Treatment of Uveitis. 2013.

Study Design

  1. Study design: The efficacy of YUTIQ was assessed in 2 randomized, multicenter, sham-controlled, double-masked, phase 3 studies in adult patients [N=282] with noninfectious uveitis affecting the posterior segment of the eye. The primary endpoint in both studies was the proportion of patients who experienced recurrence of uveitis in the study eye within 6 months of follow-up; recurrence was also assessed at 12 months. Recurrence was defined as either deterioration in visual acuity, vitreous haze attributable to noninfectious uveitis, or the use of confounding medications.1

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023.
  2. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-007
  3. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-008